This Article Extract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zatz, R. Articles by Baylis, C. Search for Related Content PubMed PubMed Citation Articles by Zatz, R. Articles by Baylis, C.

(Hypertension. 1998;32:958-964.)
© 1998 American Heart Association, Inc.

Review

Chronic Nitric Oxide Inhibition Model Six Years On

Roberto Zatz; Christine Baylis

From the Renal Division, Department of Clinical Medicine, Faculty of Medicine, University of São Paulo, São Paulo, Brazil (R.Z.); and the Department of Physiology, West Virginia University, Morgantown, WVa (C.B.).

Correspondence to Dr Roberto Zatz, Laboratório de Fisiopatologia Renal, Av. Dr. Arnaldo, 455, 3-s/67, 01246-903 São Paulo SP, Brazil.

Key Words: models • cardiovascular diseases • nitric oxide synthase • nitric oxide • blood pressure • renin-angiotensin system • vasodilation

	Introduction

Top Introduction Ubiquity and Heterogeneity of...... Renal and Hemodynamic Effects... Development of the Chronic... Mechanisms of Hypertension in... Chronic NOS Inhibition as... Summary and Perspectives References

 
The discovery in 1987 that endothelium-derived nitric oxide (NO) mediates the vasodilatory effect of certain endothelium-dependent agonists^{1 2} inaugurated the current huge field of NO biology. It is now recognized that NO plays essential roles in many diverse physiological processes and in some pathophysiologic events. Development of these concepts has been based largely on evidence obtained by limiting NO biosynthesis. This review is centered on the cardiovascular and particularly the renal functional and structural consequences of chronic pharmacologic NO inhibition by L-arginine analogues. We devoted special attention to the mechanisms of hypertension and organ injury that occur under these circumstances, while appreciating the inherent limitations surrounding interpretation of this data.

	Ubiquity and Heterogeneity of NO Biosynthesis

Top Introduction Ubiquity and Heterogeneity of...... Renal and Hemodynamic Effects... Development of the Chronic... Mechanisms of Hypertension in... Chronic NOS Inhibition as... Summary and Perspectives References

 
NO is made by the enzymatic action of several widely distributed NO synthases (NOS). In the presence of the substrates L-arginine and oxygen, as well as a number of essential cofactors, NO is produced in response to appropriate stimuli. The constitutively expressed NOS play a major role in the physiological control of vascular tone and kidney function.^{3 4} Vascular endothelial NOS (eNOS) and brain-type NOS (bNOS) are widely distributed throughout the kidney⁵ as well as the cardiovascular system and in strategic locations in the peripheral and central nervous system (CNS).^{6 7}

Both eNOS and particularly bNOS are abundant in the kidney, glomeruli, and vasculature as well as in most segments of the tubule,^{3 5} and NOS activity in medulla is considerably greater than in cortex.⁸ NO generated within the kidney controls the glomerular filtration rate (GFR), total renal and medullary blood flow, pressure natriuresis, epithelial sodium transport, and production of various vasoactive factors including renin.^{3 4 5} eNOS is distributed throughout most parts of the arterial and venous circulation, although there is considerable heterogeneity in the extent to which NO controls tone in regional circulations.⁹ Although there is some basal NO release from eNOS, shear stress is the physiologically important regulator of vascular NO production.³ In the CNS, NO is made in the nucleus tractus solitarius, the paraventricular nucleus, and the ventral medulla and can control sympathetic outflow.^{6 10} In addition to central regulation of efferent renal sympathetic nerve activity, there is direct nitrergic innervation to several locations including the renal vasculature.⁷

Inducible NOS (iNOS) can be activated in many cell types in response to immunologic challenge, but there is some localized low-level constitutive iNOS expression in kidney and vascular smooth muscle. Whether this influences blood pressure (BP) and/or kidney function is unclear.³ Recent evidence has implicated iNOS-derived NO in the pathogenesis of tissue injury in a variety of processes, although a detailed analysis of this hypothetical "dark side" of NO is beyond the scope of this review.

	Renal and Hemodynamic Effects of Acute NOS Inhibition

Top Introduction Ubiquity and Heterogeneity of...... Renal and Hemodynamic Effects... Development of the Chronic... Mechanisms of Hypertension in... Chronic NOS Inhibition as... Summary and Perspectives References

 
Determination of the biosynthetic pathways leading to NO formation set the scene for investigation of the regulatory roles of endogenous NO. In 1989, Rees et al¹¹ showed that the abrupt interruption of NO synthesis with the N^G-substituted L-arginine analogue N^G-monomethyl-L-arginine (L-NMMA) markedly elevated BP in rabbits, an effect that was abrogated by administration of excess L-arginine. Other investigators confirmed this finding in several species including humans,^{12 13} which demonstrated that by promoting a constant vasorelaxing effect, NO was an important modulator of the circulatory function.

The role of NO in the regulation of kidney function was soon investigated. Acute systemic NOS inhibition with several L-arginine analogues produced intense renal vasoconstriction with marked reduction of renal plasma flow and a smaller reduction in GFR. These effects were seen in several species and were apparent in the awake and the anesthetized animal.^{3 4} Because of the pressor effect of acute systemic NOS inhibition, some of the increased renal vascular resistance was autoregulatory; however, intrarenal local and low-dose systemic NOS inhibition produced renal vasoconstriction in the absence of increased BP.^{3 14} Thus, NO tonically generated within the kidney lowers renal vascular resistance. Zatz and De Nucci,¹⁵ using glomerular micropuncture, showed that acute systemic NOS inhibition led to both afferent and efferent arteriolar vasoconstriction, which together with the rise in BP resulted in large increases in glomerular BP; these findings were subsequently confirmed by others.^{16 17} In addition, the glomerular capillary ultrafiltration coefficient (K_f) fell,^{15 16 17} probably due to mesangial cell contraction.¹⁸ In contrast, local intrarenal NOS inhibition, without a rise in systemic BP, led to a smaller increase in afferent arteriolar resistance (R_A) but unexpectedly had no effect on the efferent arteriolar resistance (R_E), although the K_f-reducing effect was preserved.¹⁶

Control of glomerular microcirculation by NO is complex, involving direct regulation of tone by locally derived NO from eNOS, tubuloglomerular feedback control (via macula densa bNOS), and possible regulation via nitrergic renal nerves,⁷ as well as by indirect actions mediated via other vasoactive control systems.³ In addition, NO regulates sodium excretion.³ NO was shown to act directly on tubular epithelium to inhibit reabsorption,^{19 20} to be activated by sodium loading,²¹ at least in the kidney and the CNS,^{22 23 24} and to be involved in the pressure natriuresis.²⁵ Despite these natriuretic actions of NO, sodium excretion was markedly increased with a pressor dose of NOS inhibitor,²⁶ possibly secondary to the increased BP, although other unknown factors may also be involved.³

	Development of the Chronic NOS Inhibition Model

Top Introduction Ubiquity and Heterogeneity of...... Renal and Hemodynamic Effects... Development of the Chronic... Mechanisms of Hypertension in... Chronic NOS Inhibition as... Summary and Perspectives References

 
The fact that abrupt interruption of NO synthesis leads to hypertension and renal vasoconstriction does not necessarily imply that NO is indispensable in the control of circulation on a chronic basis, since other vasodilating systems might be recruited in the long run to compensate for NO deficiency. However, it was soon proven that NO does play an essential role in the long-term regulation of BP. In 1992, both of our research groups, working independently, showed that chronic administration of an orally active inhibitor of NO synthesis, N-nitro-L-arginine methyl ester (L-NAME), promoted persistent hypertension and renal damage. Baylis et al²⁷ showed that administration of L-NAME for 8 weeks led to the development of stable hypertension and glomerulosclerosis. By use of a much higher dose of L-NAME, Ribeiro et al²⁸ obtained a severe and progressive form of hypertension associated with glomerular ischemia, glomerulosclerosis, and renal interstitial expansion. Two other groups reported simultaneously or soon thereafter the development of hypertension associated with chronic L-NAME treatment.^{29 30} These findings, subsequently confirmed by other researchers, indicated that NO is a fundamental and irreplaceable element in the regulation of BP and gave birth to a new model of arterial hypertension.

It was later shown that knockout mice lacking the gene for the endothelial isoform of NOS developed systemic and pulmonary hypertension,^{31 32} whereas deletion of the genes encoding the neuronal and inducible isoforms, respectively, led to no detectable circulatory changes.^{33 34} Although these observations initially suggested that NO derived from eNOS, but not from bNOS or iNOS, is crucial to the maintenance of normal circulatory function, human studies indicated no genetic linkage between eNOS and essential hypertension,^{35 36} whereas more recent experimental evidence has strongly implicated an important role for NO derived from bNOS in influencing the tubuloglomerular feedback³⁷ and/or the sympathetic nervous system (SNS).^{6 38 39}

The following sections discuss the mechanisms involved in sustaining high BP during chronic nonselective NOS inhibition, revealing that in fact this is a very complex model of hypertension.

	Mechanisms of Hypertension in the Chronic NOS Inhibition Model

Top Introduction Ubiquity and Heterogeneity of...... Renal and Hemodynamic Effects... Development of the Chronic... Mechanisms of Hypertension in... Chronic NOS Inhibition as... Summary and Perspectives References

 
Sustained BP elevation requires the persistence of at least 1 of the following abnormalities: (1) increased cardiac output, (2) increased peripheral resistance, or (3) impaired renal ability to excrete sodium (Guyton's hypothesis).⁴⁰ Because the available evidence suggests that cardiac output is actually decreased in chronic NOS inhibition,⁴¹ we will consider the possible factors leading to systemic vasoconstriction and/or salt retention in the chronic NOS inhibition model.

Lack of Tonic Vasodilation
Since the first experiments with acute inhibition of NOS, the concept has emerged that the hemodynamic changes thus obtained reflect the abrupt withdrawal of a tonic vasodilator effect, leaving unopposed an equally tonic action of endogenous vasoconstrictors. This notion was supported by the observation that under certain conditions the effects of acute NO inhibition could be at least partly reversed by inhibition of vasoconstrictors such as angiotensin II (Ang II),⁴² vasopressin,⁴³ or endothelin⁴⁴ and that the renal vasoconstrictor response to Ang II was augmented by acute NO inhibition.⁴⁵ If persistent unmodulated vasoconstriction is indeed responsible for the maintenance of hypertension in the chronic NOS inhibition model, then either acute or chronic inhibition of the vasoactive principle(s) underlying peripheral vasoconstriction in this model should completely reverse hypertension. There is now considerable evidence that both Ang II and the SNS contribute to the hypertension of chronic NOS inhibition, as discussed in detail below.

Data are inconsistent regarding the effect of administration of excess exogenous L-arginine, which in principle would be expected to competitively reverse NOS inhibition and therefore abrogate L-NAME–induced hypertension. This did occur when L-arginine treatment was begun simultaneously with NO inhibition.⁴⁶ After NO inhibition had been maintained for 1 week, however, correction of hypertension with acute L-arginine was only partial,²⁸ and an even smaller effect was obtained in rats that had been treated for 4 to 6 weeks.^{47 48} Of interest, although Ribeiro et al²⁸ showed that hypertension regressed when the NO inhibitor was withdrawn after 4 weeks of treatment, Morton et al⁴⁹ observed persistent hypertension even after NO inhibition was discontinued after 14 weeks of treatment. These observations suggest that once NO has been inhibited for more than a few days, the hypertension no longer depends exclusively on inactivation of the L-arginine/NO pathway. The pathogenic mechanisms attending this late autonomous phase of the model are unclear and may involve structural alteration of the vascular walls,^{49 50} as well as renal parenchymal injury such as glomerulosclerosis, glomerular collapse, and interstitial fibrosis.^{27 28 51} In addition, abnormal activation of the renin-angiotensin system (RAS), initiated during L-NAME treatment, may fail to subside after NO inhibition is discontinued (see below).

Role of the RAS
Studies of acute inhibition of Ang II in the chronic NOS inhibition model have yielded inconclusive results. Zanchi et al⁵² obtained a large BP reduction with angiotensin type 1 (AT₁) receptor blockade, whereas Bank et al⁵³ and Baylis et al³⁹ observed little effect of Ang II blockade on BP or renal hemodynamics in rats with chronic NOS inhibition. However, combined acute inhibition of both Ang II and -adrenergic receptors reversed L-NAME–associated hypertension almost completely,³⁹ raising the possibility that the state of generalized vasoconstriction characteristic of the chronic NOS inhibition model is maintained by an interaction between the SNS (see below) and the RAS.

Ribeiro et al²⁸ showed that concomitant chronic administration of the Ang II receptor antagonist losartan to rats chronically treated with L-NAME prevented both the hypertension and the renal injury associated with this model, suggesting a key participation of the RAS in these events. These findings have been corroborated in several subsequent studies that involved chronic administration of either Ang II receptor antagonists or angiotensin-converting enzyme inhibitors.^{54 55} In addition, chronic Ang II blockade reversed established hypertension⁵⁶ and reduced persistent hypertension after discontinuation of NOS inhibition,⁴⁹ raising the interesting possibility that the RAS plays a causative or permissive role in L-NAME hypertension even after NO inhibition is interrupted.

Beside modulating the effects of chronic NO inhibition, the RAS in turn may be influenced by this treatment, although the very direction of this relationship is still a matter of controversy. Plasma renin activity (PRA) was reported to be increased,²⁸ unchanged,⁵⁷ or decreased^{29 56} in this model of hypertension. Several in vitro studies provided evidence that NO might act as an inhibitor of renin release.^{58 59} However, other in vitro observations⁶⁰ and experiments in isolated perfused kidneys⁶¹ suggested that NO stimulates the synthesis and/or secretion of renin. In addition, several investigators reported decreased circulating renin in the chronic NOS inhibition model,^{28 29 51 62 63} even in animals in which PRA was initially elevated by restricted dietary sodium intake⁶² or reduction of renal perfusion pressure.⁶³ Only when L-NAME treatment lasted long enough to result in significant renal structural injury did renin levels rise as an epiphenomenon,^{28 51 62} although recent evidence obtained by Baylis et al⁶⁴ suggested that even this late rise in PRA may be only transient. Thus, circulating PRA is unpredictable and bears no consistent relationship with the protective action of chronic Ang II blockade. Perhaps the Ang II dependence of chronic NOS inhibition hypertension is associated with normal or increased tissue Ang II levels,⁶⁵ increased sensitivity to Ang II,⁶⁶ and/or an interaction between Ang II and the SNS.³⁹

An anatomic basis for the complex interaction between NO and the RAS is provided by the observation that neuronal NOS (nNOS) is particularly abundant in the macula densa,^{67 68} consistent with a mediatory or permissive role of NO in the process of renin release from the juxtaglomerular apparatus. Indeed, selective bNOS inhibition blunted the increase in renin secretion induced by furosemide treatment, which is likely to originate from macula densa signaling, but failed to prevent hyperreninemia associated with lowering renal perfusion pressure, which is linked to baroreceptor stimulation.⁶⁹ Likewise, acute bNOS inhibition limited the increase in renin secretion observed in salt-depleted rats.⁷⁰

Role of the CNS and the SNS
As with Ang II, acute inhibition of the SNS in the chronic NOS inhibition model has produced variable results, with both a substantial fall⁵² and little change in BP^{39 53} being reported during acute -adrenergic receptor blockade. Acute ganglionic blockade, however, produced a large fall in BP in rats with chronic NOS inhibition, which was exacerbated compared with the depressor response of controls. Also, chronic sympathectomy by daily injections of ganglionic blockers attenuated the hypertension that resulted from 1 week of chronic L-NAME administration,⁷¹ suggesting that increased central sympathetic drive may be involved in chronic NOS inhibition hypertension.⁷¹ Indeed, NOS inhibitors that are given systemically cross the blood-brain barrier and produce local NOS inhibition in the CNS as well as in the circulation.⁷² Because acutely administered NOS inhibitors given directly into some areas of the CNS produce hypertension,⁶ some of the pressor response to systemic NOS inhibition may result from NOS blockade in strategic areas of the CNS. Part of this involvement of the SNS in chronic NOS inhibition may result from an increased sensitivity of vascular smooth muscle to -adrenoceptor stimulation.⁷³ Elegant studies in the conscious rat have recently demonstrated that the role of the SNS varies with the duration of NOS inhibition,⁷⁴ which may explain some of the variable findings with acute inhibition of the -adrenoceptor.

There is some evidence for a specific involvement of the renal nerves, since chronic bilateral renal denervation delayed and attenuated hypertension in rats with chronic NOS inhibition.⁷⁵ These effects may be partly mediated via a reduction in sensitivity of the baroreceptor reflex, which contributes permissively to L-NAME hypertension.⁷⁶ In contrast, other investigators have reported evidence that renal nerve traffic plays little or no role in the hypertension of chronic NOS inhibition.⁷⁷ The relationship between NO and the SNS is likely to be highly complex, with direct interactions at the various adrenergic receptor subtypes and indirect interactions through baroreceptor control of BP, for example, providing numerous and sometimes opposing influences. The variability in the literature presumably is related to this complexity.

Role of Endothelin
Unlike the results obtained with Ang II inhibition, neither acute⁵³ nor chronic endothelin (ET) inhibition with either a specific ET_A or a combined ET_A/ET_B antagonist had any effect on either hypertension or renal injury in rats given chronic L-NAME treatment.^{78 79} In a recent study, the alternative NOS inhibitor N-nitro-L-arginine (L-NNA) was given in high doses for 3 weeks; here, concomitant chronic ET_A receptor blockade attenuated the hypertension and vascular damage and prevented the glomerular ischemia and proteinuria.⁸⁰ Possible reasons for differences between L-NNA– and L-NAME–induced chronic hypertension are discussed below. At present, the role played by ET in the pathogenesis of hypertension in this model remains uncertain.

Role of Calcium Channels
There is abundant evidence that NO modulates the activity of both L-type calcium channels and calcium release channels (ryanodyne receptor channels), thus profoundly influencing cell metabolism, especially in excitable tissue.^{81 82} Therefore, the dramatic changes observed in the chronic NOS inhibition model may reflect at least in part defective intracellular calcium metabolism. Consistent with this view, several studies showed a marked effect of calcium channel inhibitors in this model. Acute blockade of voltage-dependent calcium channels with verapamil in rats that had received L-NAME for 3 weeks reversed the hypertension,⁵³ whereas concomitant chronic treatment with verapamil⁵⁵ prevented hypertension in rats subjected to chronic NOS inhibition for 6 weeks. Similarly, Ribeiro et al⁸³ showed that chronic treatment with nifedipine attenuated hypertension and prevented renal injury in rats receiving L-NAME for 4 weeks, whereas Erley et al⁴⁸ showed attenuation of hypertension but not renal functional amelioration with the simultaneous use of felodipine in rats receiving L-NAME for 12 weeks. Together, these observations suggest that the presence of endogenous vasoconstrictors, especially Ang II, and an adequate operation of voltage-gated calcium channels are necessary for the hemodynamic and cellular actions caused by chronic L-NAME treatment to take place.

Role of Salt Retention
According to Guyton,⁴⁰ arterial hypertension results from an impaired renal ability to excrete sodium. Because of this primary defect, BP will rise until renal sodium excretion is increased (by pressure natriuresis) to again equal sodium intake. NO may play a key role in this process of pressure natriuresis. Mattson and Higgins²³ showed that sodium overload induces a large increase in medullary NO generation. In a related study, these investigators performed a chronic infusion of L-NAME in the rat renal medullary area and observed the development of sustained hypertension, which regressed on discontinuation of the infusion.⁸⁴ Furthermore, although renal NO production is increased in response to dietary salt overload in the Dahl salt-resistant rat, this response is greatly attenuated in Dahl salt-sensitive rats.⁸⁵ L-Arginine administration restores NO production and prevents salt-induced hypertension in Dahl salt-sensitive rats.⁸⁵

From the evidence discussed above, it might be inferred that the level of salt intake would profoundly influence the development of hypertension in the chronic NOS inhibition model. Indeed, Fujihara et al⁵¹ and Tolins and Schultz⁸⁶ showed that administration of a high salt diet aggravated hypertension and renal injury in rats given chronic treatment with L-NAME. Conversely, Romero et al^{30 87} showed that dietary salt restriction completely prevented development of hypertension in this model. Nevertheless, other investigators observed no impact of varying salt intake on L-NAME–induced hypertension.^{57 88} Of note, the doses of NOS inhibitor used in these studies varied considerably. Even in the original studies 6 years ago, Ribeiro et al²⁸ and Baylis et al²⁷ used widely differing doses of L-NAME (70 mg · kg^-1 · d^-1 and 5 mg · kg^-1 · d^-1, respectively). A range of intermediary doses has been used since then. To investigate whether the extent of NO inhibition could influence salt sensitivity, Yamada et al⁶² compared the effects of salt intake in rats receiving 2 different doses of L-NAME. They confirmed previous observations⁸⁶ that the pattern of salt sensitivity observed in Dahl rats can be reproduced by chronic treatment with a low nonpressor dose of L-NAME. The slope of the pressure-natriuresis line was significantly reduced in these animals, indicating limited renal ability to excrete sodium. In rats treated with a much higher pressor dose of L-NAME, however, hypertension persisted even after severe dietary salt restriction. In these rats, the pressure-natriuresis line and the x intercept were shifted to the right, but the slope of the line was unchanged compared with normal animals, predicting low salt sensitivity and persistence of hypertension even with no salt intake. In fact, this high-dose L-NAME model is associated with immediate and persistent volume depletion during the evolution of hypertension.⁶⁴

Taken as a whole, these data indicate that the chronic NOS inhibition model may actually follow 3 different patterns, depending on the extent of NO inhibition. (1) Very low doses of NOS inhibitor do not directly raise systemic vascular resistance and produce a purely volume-dependent hypertension.⁶² (2) An intermediate dose, which causes widespread partial NOS inhibition,²⁷ elicits a hypertension that is substantial but stable and that does not progress over a 2-month period. (3) High-grade, near-complete NOS inhibition promotes renal and systemic vasoconstriction to such a degree as to obscure any beneficial effect of salt restriction. This hypertension is progressive despite administration of a constant dose of inhibitor throughout. These animals develop rapidly progressive and malignant hypertension with severe vascular and parenchymal damage, particularly at the kidneys. The original study reported by Ribeiro et al²⁸ represents an archetype of this third modality of L-NAME hypertension.

Role of Arachidonic Acid Derivatives
There is a considerable amount of cross-talk between the NO system and the various arachidonic acid derivative pathways. There is clearly stimulation of prostanoids from the inducible cyclooxygenase isoform (COX-2) by iNOS-derived NO,⁸⁹ but the relationship between constitutively derived NO and cyclooxygenase products is less clear. Prostacyclin (PGI₂) inhibits NO release from cultured endothelial cells,⁹⁰ possibly via a cAMP-mediated action.⁹¹ In the dog kidney, the full renal vasodilatory potential of NO (or PGI₂) is expressed only in the presence of prostaglandin (or NO) inhibition, suggesting that these autacoids are mutually antagonistic on each other's synthesis/release.⁹² Nevertheless, acute cyclooxygenase inhibition does not aggravate hypertension in rats treated chronically with L-NAME, although additional renal vasoconstriction does occur.⁹³

In general, NO reversibly binds with the heme-containing moieties of a number of enzymes, including cytochrome P450 enzymes,⁹⁴ thus tonically inhibiting their products. For example, NO apparently inhibits the lipoxygenase pathway in some tissues,⁹⁵ and there is recent evidence that NO tonically inhibits production of 20-HETE by the P4504A enzyme.⁹⁴ Furthermore, 20-HETE plays a significant role in the vasoconstrictor response to acute NOS inhibition in the kidney and systemic vasculature,⁹⁴ although the importance of this system in responses to chronic NOS inhibition has not been investigated. However, it is likely that some of the constrictor responses seen with chronic NOS inhibition may result from enhancement of the actions of various vasoconstrictor arachidonic acid products.

Role of Other Factors
Because of the ubiquitous nature of NO, many cellular processes are likely to be distorted as a result of chronic inhibition of NO. NO plays an important role in apoptosis in some circumstances⁹⁶ and exerts mainly antiproliferative actions in the vasculature⁹⁷; thus chronic removal of NO will lead directly to increased tissue mass. In addition to inhibition of all NOS isoforms, chronic L-NAME treatment may have other unrelated effects that can affect hypertension and/or kidney dysfunction. For example, the cardiac hypertrophy seen with L-NAME–induced hypertension is much less than that with equivalent degrees of hypertension produced by other maneuvers,⁹⁸ suggesting that NOS inhibition (or at least L-NAME) may exert some direct antiproliferative actions. Because NO is itself mainly antiproliferative,⁹⁷ this implies a nonselective action of L-NAME, possibly via its known antimuscarinic effects⁸⁰ and perhaps by inhibition of ornithine decarboxylase⁹⁹ or some other nonspecific inhibitory action on cardiovascular growth(s). It is certainly true that the features of high-dose chronic L-NAME–induced hypertension and kidney damage differ from chronic L-NNA in some respects,⁸⁰ which emphasizes the probability that unrelated side effects of these L-arginine analogues probably contribute to the pathology in this model.

	Chronic NOS Inhibition as a Model of Organ Damage

Top Introduction Ubiquity and Heterogeneity of...... Renal and Hemodynamic Effects... Development of the Chronic... Mechanisms of Hypertension in... Chronic NOS Inhibition as... Summary and Perspectives References

 
In addition to its pronounced effect on circulatory function, chronic NOS inhibition can deeply affect the structure of the vasculature, including the renal architecture and myocardial and nervous tissue. A variety of parenchymal lesions has been found, especially in the kidney, which so far has been the best-studied target organ in this model.

Five modalities of renal injury have been described in conjunction with chronic NOS inhibition: (1) Classic glomerulosclerosis^{27 28 51 62} consists of glomerular accumulation of hyaline material with collapse of capillary loops and adhesion to the parietal layer of Bowman's capsule. (2) Glomerular ischemia consists of uniform collapse of the glomerular tuft and the capillary loops with pronounced thickening and even duplication of the basement membrane.^{28 51 62} This abnormality has been shown previously in association with human essential hypertension.¹⁰⁰ It has also been described in the neighborhood of the scarred areas in the renal ablation model.¹⁰¹ These glomeruli are likely responsible for the enhanced renin secretion observed in the late phases of the chronic NOS inhibition model, although direct evidence favoring this hypothesis is lacking. (3) Glomerular segmental necrosis^{28 51 62} appears as sharply delimited areas where lysis of necrotic material may result in the formation of microaneurysms. (4) Interstitial expansion^{28 51 62} shows infiltration by fibroblasts and deposition of collagen-like material along with tubular atrophy and vacuolization. (5) Microvascular lesions^{28 51 62} range from arteriolar wall thickening to "onion skin" proliferation with complete luminal occlusion, fibrinoid necrosis of the vascular wall, and periarteriolar fibrosis. All these types of renal injury are associated with progressive albuminuria,^{27 51 62} which can be amplified nearly to the nephrotic range by concomitant salt overload,^{51 62} indicating that functional impairment of the glomerular wall barrier also occurs in this model. The functional and structural grounds for this latter abnormality are unknown. However, preliminary evidence has been reported that progressive depletion of negative charge in the glomerular basement membrane occurs in rats receiving L-NAME for 1 month. Concomitant salt overload aggravates this abnormality and promotes the appearance of a size defect, which may explain the massive albuminuria observed in this setting.¹⁰²

Tissue injury associated with chronic NOS inhibition is not confined to the kidney. Rats receiving chronic L-NAME treatment exhibit focal areas of myocardial necrosis along with focal areas of fibrosis that may reflect organization of necrotic tissue.^{98 103} The development of these lesions could not be ascribed to either systemic hypertension¹⁰³ or activation of the RAS,¹⁰⁴ suggesting that NO inhibition may exert a specific deleterious effect on the myocardium. Chronic NOS inhibition may also severely damage the CNS. For example, a 100% incidence of stroke was described in rats receiving an NO inhibitor for up to 6 months,¹⁰⁵ and a 79% incidence of motor dysfunction was described in rats treated with L-NAME for 11 weeks. At autopsy, spinal cord infarcts were encountered in 90% of these animals; 30% exhibited brain lesions as well.¹⁰⁶ These observations may help to explain the high mortality observed in the chronic NOS inhibition model.^{28 51 62}

	Summary and Perspectives

Top Introduction Ubiquity and Heterogeneity of...... Renal and Hemodynamic Effects... Development of the Chronic... Mechanisms of Hypertension in... Chronic NOS Inhibition as... Summary and Perspectives References

 
Since the advent of the chronic NOS inhibition model, it has become clear that NO is an indispensable and irreplaceable element in the maintenance of circulatory integrity, regulating such diverse functions as vascular tone, renal salt excretion, and renin secretion. Further investigation is needed to establish the relative importance of NO derived from the various NOS isoforms in controlling renal and systemic hemodynamics in health or disease.

Received June 10, 1998; first decision July 7, 1998; accepted August 24, 1998.

	References

Top Introduction Ubiquity and Heterogeneity of...... Renal and Hemodynamic Effects... Development of the Chronic... Mechanisms of Hypertension in... Chronic NOS Inhibition as... Summary and Perspectives References

 
1. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biologic activity of endothelium-derived relaxing factor. Nature. 1987;327:524–526.[Medline] [Order article via Infotrieve]

2. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 1987;84:9265–9269.[Abstract/Free Full Text]

3. Kone BC, Baylis C. Biosynthesis and homeostatic roles of nitric oxide in the kidney. Am J Physiol. 1997;272:F561–F578.[Abstract/Free Full Text]

4. Ito S. Nitric oxide in the kidney. Curr Opin Nephrol Hypertens. 1995;4:23–30.[Medline] [Order article via Infotrieve]

5. Bachmann S, Mundel P. Nitric oxide in the kidney: synthesis, localization, and function. Am J Kidney Dis. 1994;24:112–129.[Medline] [Order article via Infotrieve]

6. Tseng CJ, Liu HY, Lin HC, Ger LP, Tung CS, Yen MH. Cardiovascular effects of nitric oxide in the brain stem nuclei of rats. Hypertension. 1996;27:36–42.[Abstract/Free Full Text]

7. Okamura T, Yoshida K, Toda N. Nitroxidergic innervation in dog and monkey renal arteries. Hypertension. 1995;25:1090–1095.[Abstract/Free Full Text]

8. Zou AP, Cowley AW. Nitric oxide in renal cortex and medulla. An in vivo microdialysis study. Hypertension. 1997;29:194–198.[Abstract/Free Full Text]

9. Boegehold MA. Heterogeneity of endothelial function within the circulation. Curr Opin Nephrol Hypertens. 1998;7:71–78.[Medline] [Order article via Infotrieve]

10. Zhang K, Mayhan WG, Patel KP. Nitric oxide within the paraventricular nucleus mediates changes in renal sympathetic nerve activity. Am J Physiol. 1997;273:R864–R872.[Abstract/Free Full Text]

11. Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A. 1989;86:3375–3378.[Abstract/Free Full Text]

12. Haynes WG, Noon JP, Walker BR, Webb DJ. Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens. 1993;11:1375–1380.[Medline] [Order article via Infotrieve]

13. Wolzt M, Schmetterer L, Ferber W, Artner E, Mensik C, Eichler HG, Krejcy K. Effect of nitric oxide synthase inhibition on renal hemodynamics in humans: reversal by L-arginine. Am J Physiol. 1997;272:F178–F182.[Abstract/Free Full Text]

14. Granger JP, Alberola AM, Salazar FJ, Nakamura T. Control of renal hemodynamics during intrarenal and systemic blockade of nitric oxide synthesis in conscious dogs. J Cardiovasc Pharmacol. 1992;20:S160–S162.

15. Zatz R, De-Nucci G. Effects of acute nitric oxide inhibition on rat glomerular microcirculation. Am J Physiol. 1991;261:F360–F363.[Abstract/Free Full Text]

16. Deng A, Baylis C. Locally produced EDRF controls preglomerular resistance and ultrafiltration coefficient. Am J Physiol. 1993;264:F212–F215.[Abstract/Free Full Text]

17. De-Nicola L, Blantz RC, Gabbai FB. Nitric oxide and angiotensin II. Glomerular and tubular interaction in the rat. J Clin Invest. 1992;89:1248–1256.

18. Schultz PJ, Schorer AE, Raij L. Effects of endothelium-derived relaxing factor and nitric oxide on rat mesangial cells. Am J Physiol. 1990;258:F162–F167.[Abstract/Free Full Text]

19. McKee M, Scavone C, Nathanson JA. Nitric oxide, cGMP, and hormone regulation of active sodium transport. Proc Natl Acad Sci U S A. 1994;91:12056–12060.[Abstract/Free Full Text]

20. Stoos BA, Garcia NH, Garvin JL. Nitric oxide inhibits sodium reabsorption in the isolated perfused cortical collecting duct. J Am Soc Nephrol. 1995;6:89–94.[Abstract]

21. Shultz PJ, Tolins JP. Adaptation to increased dietary salt intake in the rat. Role of endogenous nitric oxide. J Clin Invest. 1993;91:642–650.

22. Deng X, Welch WJ, Wilcox CS. Renal vasoconstriction during inhibition of NO synthase: effects of dietary salt. Kidney Int. 1994;46:639–646.[Medline] [Order article via Infotrieve]

23. Mattson D, Higgins DJ. Influence of dietary sodium intake on renal medullary nitric oxide synthase. Hypertension. 1996;27:688–692.[Abstract/Free Full Text]

24. Villar MJ, Cecatelli S, Ronnqvist M, Hokfelt T. Nitric oxide synthase increases in hypothalamic magnocellular neurons after salt loading in the rat. An immunohistochemical and in situ hybridization study. Brain Res. 1994;644:273–281.[Medline] [Order article via Infotrieve]

25. Salom MG, Lahera V, Miranda-Guardiola F, Romero JC. Blockade of pressure natriuresis induced by inhibition of renal synthesis of nitric oxide in dogs. Am J Physiol. 1992;262:F718–F722.[Abstract/Free Full Text]

26. Baylis C, Harton P, Engels K. Endothelium-derived relaxing factor controls renal hemodynamics in the normal rat kidney. J Am Soc Nephrol. 1990;1:875–881.[Abstract]

27. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest. 1992;90:278–281.

28. Ribeiro MO, Antunes E, De-Nucci G, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis: a new model of arterial hypertension. Hypertension. 1992;20:298–303.[Abstract/Free Full Text]

29. Arnal JF, Warin L, Michel JB. Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J Clin Invest. 1992;90:647–652.

30. Lahera V, Salazar J, Salom MG, Romero JC. Deficient production of nitric oxide induces volume-dependent hypertension. J Hypertens. 1992;10(suppl):S173–S177.

31. Huang PL, Huang ZH, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995;377:239–242.[Medline] [Order article via Infotrieve]

32. Steudel W, Ichinose F, Huang PL, Hurford WE, Jones RC, Bevan JA, Fishman MC, Zapol WM. Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene. Circ Res. 1997;81:34–41.[Abstract/Free Full Text]

33. Nelson RJ, Demas GE, Huang PL, Fishman MC, Dawson VL, Dawson TM, Snyder SH. Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase. Nature. 1995;378:383–386.[Medline] [Order article via Infotrieve]

34. Laubach VE, Shesely EG, Smithies O, Sherman PA. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc Natl Acad Sci U S A. 1995;92:10688–10692.[Abstract/Free Full Text]

35. Bonnardeaux A, Nadaud S, Charru A, Jeunemaitre X, Corvol P, Soubrier F. Lack of evidence for linkage of the endothelial cell nitric oxide synthase gene to essential hypertension. Circulation. 1995;91:96–102.[Abstract/Free Full Text]

36. Hunt SC, Williams CS, Sharma AM, Inoue I, Williams RR, Lalouel JM. Lack of linkage between the endothelial nitric oxide synthase gene and hypertension. J Hum Hypertens. 1996;10:27–30.[Medline] [Order article via Infotrieve]

37. Ollerstam A, Pittner J, Persson AEG, Thorup C. Increased blood pressure in rats after long-term inhibition of the neuronal isoform of nitric oxide synthase. J Clin Invest. 1997;99:2212–2218.[Medline] [Order article via Infotrieve]

38. Kumagai K, Suzuki H, Ichikawa M, Jimbo M, Murakami M, Ryuzaki M, Saruta T. Nitric oxide increases renal blood flow by interacting with the sympathetic nervous system. Hypertension. 1994;24:220–226.[Abstract/Free Full Text]

39. Qiu C, Engels K, Baylis C. Angiotensin II and alpha 1-adrenergic tone in chronic nitric oxide blockade-induced hypertension. Am J Physiol. 1994;266:R1470–R1476.[Abstract/Free Full Text]

40. Guyton AC. Long-term arterial pressure control: an analysis from animal experiments and computer and graphic models. Am J Physiol. 1990;259:R865–R877.[Abstract/Free Full Text]

41. Kassab S, Miller MT, Hester R, Novak J, Granger JP. Systemic hemodynamics and regional blood flow during chronic nitric oxide synthesis inhibition in pregnant rats. Hypertension. 1998;31:315–320.[Abstract/Free Full Text]

42. Sigmon DH, Carretero OA, Beierwaltes WH. Plasma renin activity and the renal response to nitric oxide synthesis inhibition. J Am Soc Nephrol. 1992;3:1288–1294.[Abstract]

43. Manning RD Jr, Hu LF, Williamson TD. Mechanisms involved in the cardiovascular-renal actions of nitric oxide inhibition. Hypertension. 1994;23:951–956.[Abstract/Free Full Text]

44. Qiu C, Engels K, Baylis C. Endothelin modulates the pressor actions of acute systemic nitric oxide blockade. J Am Soc Nephrol. 1995;6:1476–1481.[Abstract]

45. Baylis C, Harvey J, Engels K. Acute nitric oxide blockade amplifies the renal vasoconstrictor actions of angiotensin II. J Am Soc Nephrol. 1994;5:211–214.[Abstract]

46. Salazar FJ, Pinilla JM, Lopez F, Romero JC, Quesada T. Renal effects of prolonged synthesis inhibition of endothelium-derived nitric oxide. Hypertension. 1992;20:113–117.[Abstract/Free Full Text]

47. Qiu CB, Engels K, Samsell L, Baylis C. Renal effects of acute amino acid infusion in hypertension induced by chronic nitric oxide blockade. Hypertension. 1995;25:61–66.[Abstract/Free Full Text]

48. Erley CM, Rebmann S, Strobel U, Schmidt T, Wehrmann M, Osswald H, Risler T. Effects of antihypertensive therapy on blood pressure and renal function in rats with hypertension due to chronic blockade of nitric oxide synthesis. Exp Nephrol. 1995;3:293–299.[Medline] [Order article via Infotrieve]

49. Morton JJ, Beattie EC, Speirs A, Gulliver F. Persistent hypertension following inhibition of nitric oxide formation in the young Wistar rat: role of renin and vascular hypertrophy. J Hypertens. 1993;11:1083–1088.[Medline] [Order article via Infotrieve]

50. Deng LY, Thibault G, Schiffrin EL. Effect of hypertension induced by nitric oxide synthase inhibition on structure and function of resistance arteries in the rat. Clin Exp Hypertens. 1993;15:527–537.

51. Fujihara CK, Michellazzo SM, De-Nucci G, Zatz R. Sodium excess aggravates hypertension and renal parenchymal injury in rats with chronic NO inhibition. Am J Physiol. 1994;266:F697–F705.[Abstract/Free Full Text]

52. Zanchi A, Schaad NC, Osterheld MC, Grouzmann E, Nussberger J, Brunner HR, Waeber B. Effects of chronic NO synthase inhibition in rats on renin-angiotensin system and sympathetic nervous system. Am J Physiol. 1995;268:H2267–H2273.[Abstract/Free Full Text]

53. Bank N, Aynedjian HS, Khan GA. Mechanism of vasoconstriction induced by chronic inhibition of nitric oxide in rats. Hypertension. 1994;24:322–328.[Abstract/Free Full Text]

54. Navarro-Cid J, Maeso R, Rodrigo E, Munoz-Garcia R, Ruilope LM, Lahera V, Cachofeiro V. Renal and vascular consequences of the chronic nitric oxide synthase inhibition. Effects of antihypertensive drugs. Am J Hypertens. 1996;9:1077–1083.[Medline] [Order article via Infotrieve]

55. Takase H, Moreau P, Kung CF, Nava E, Luscher TF. Antihypertensive therapy prevents endothelial dysfunction in chronic nitric oxide deficiency: effect of verapamil and trandolapril. Hypertension. 1996;27:25–31.[Abstract/Free Full Text]

56. Pollock DM, Polakowski JS, Divish BJ, Opgenorth TJ. Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition. Hypertension. 1993;21:660–666.[Abstract/Free Full Text]

57. Jover B, Herizi A, Ventre F, Dupont M, Mimran A. Sodium and angiotensin in hypertension induced by long-term nitric oxide blockade. Hypertension. 1993;21:944–948.[Abstract/Free Full Text]

58. Vidal MJ, Romero JC, Vanhoutte PM. Endothelium-derived relaxing factor inhibits renin release. Eur J Pharmacol. 1988;149:401–402.[Medline] [Order article via Infotrieve]

59. Greenberg SG, He XR, Schnermann JB, Briggs JP. Effect of nitric oxide on renin secretion. 1. Studies in isolated juxtaglomerular granular cells. Am J Physiol. 1995;268:F948–F952.[Abstract/Free Full Text]

60. Tharaux PL, Dussaule JC, Pauti MD, Vassitch Y, Ardaillou R, Chatziantoniou C. Activation of renin synthesis is dependent on intact nitric oxide production. Kidney Int. 1997;51:1780–1787.[Medline] [Order article via Infotrieve]

61. Gardes J, Gonzalez MF, Alhenc-Gelas F, Menard J. Influence of sodium diet on L-NAME effects on renin release and renal vasoconstriction. Am J Physiol. 1994;267:F798–F804.[Abstract/Free Full Text]

62. Yamada SS, Sassaki AL, Fujihara CK, Malheiros DM, De Nucci G, Zatz R. Effect of salt intake and inhibitor dose on arterial hypertension and renal injury induced by chronic nitric oxide blockade. Hypertension. 1996;27:1165–1172.[Abstract/Free Full Text]

63. Knoblich PR, Freeman RH, Villarreal D. Pressure-dependent renin release during chronic blockade of nitric oxide synthase. Hypertension. 1996;28:738–742.[Abstract/Free Full Text]

64. Qiu C, Muchant D, Beierwaltes W, Racusen L, Baylis C. Evolution of chronic nitric oxide inhibition hypertension: relationship to renal function. Hypertension. 1998;31:21–26.[Abstract/Free Full Text]

65. Garcia GE, Brown MR, Wead LM, Braun S, Gabbai FB. Effect of reduction of nitric oxide on plasma and kidney tissue angiotensin II levels. Am J Hypertens. 1997;10:1103–1108.[Medline] [Order article via Infotrieve]

66. Conrad KP, Whittemore SL. N^G-Monomethyl-L-arginine and nitroarginine potentiate pressor responsiveness of vasoconstrictors in conscious rats. Am J Physiol. 1992;262:R1137–R1144.[Abstract/Free Full Text]

67. Wilcox CS, Welch WJ, Murad F, Gross SS, Taylor G, Levi R, Schmidt HH. Nitric oxide synthase in macula densa regulates glomerular capillary pressure. Proc Natl Acad Sci U S A. 1992;89:11993–11997.[Abstract/Free Full Text]

68. Bachmann S, Bosse HM, Mundel P. Topography of nitric oxide synthesis by localizing constitutive NO synthases in mammalian kidney. Am J Physiol. 1995;268:F885–F898.[Abstract/Free Full Text]

69. Beierwaltes WH. Selective neuronal nitric oxide synthase inhibition blocks furosemide-stimulated renin secretion in vivo. Am J Physiol. 1995;269:F134–F139.[Abstract/Free Full Text]

70. Beierwaltes WH. Macula densa stimulation of renin is reversed by selective inhibition of neuronal nitric oxide synthase. Am J Physiol. 1997;272:R1359–R1364.[Abstract/Free Full Text]

71. Cunha RS, Cabral AM, Vasquez EC. Evidence that the autonomic nervous system plays a major role in the L-NAME-induced hypertension in conscious rats. Am J Hypertens. 1993;6:806–809.[Medline] [Order article via Infotrieve]

72. Traystman RJ, Moore LE, Helfaer MA, Davis S, Banasiak K, Williams M, Hurn PD. Nitro-L-arginine analogues. Dose- and time-related nitric oxide synthase inhibition in brain. Stroke. 1995;26:864–869.[Abstract/Free Full Text]

73. Kanagy NL. Increased vascular responsiveness to alpha 2-adrenergic stimulation during NOS inhibition-induced hypertension. Am J Physiol. 1997;273:H2756–H2764.[Abstract/Free Full Text]

74. Sander M, Hansen J, Victor RG. The sympathetic nervous system is involved in the maintenance but not initiation of the hypertension induced by N-nitro-L-arginine methyl ester. Hypertension. 1997;30:64–70.[Abstract/Free Full Text]

75. Matsuoka H, Nishida H, Nomura G, Van Vliet BN, Toshima H. Hypertension induced by nitric oxide synthesis inhibition is renal nerve dependent. Hypertension. 1994;23:971–975.[Abstract/Free Full Text]

76. Scrogin KE, Veelken R, Luft FC. Sympathetic baroreceptor responses after chronic N^G-nitro-L-arginine methyl ester treatment in conscious rats. Hypertension. 1994;23:982–986.[Abstract/Free Full Text]

77. Granger J, Novak J, Schnackenberg C, Williams S, Reinhart GA. Role of renal nerves in mediating the hypertensive effects of nitric oxide synthesis inhibition. Hypertension. 1996;27:613–618.[Abstract/Free Full Text]

78. Fujihara CK, De Nucci G, Zatz R. Do ETA receptors participate in the hemodynamic and renal effects of chronic nitric oxide blockade? J Cardiovasc Pharmacol. 1995;26:S462–S465.

79. Sventek P, Turgeon A, Schiffrin EL. Vascular endothelin-1 gene expression and effect on blood pressure of chronic ETA endothelin receptor antagonism after nitric oxide synthase inhibition with L-NAME in normal rats. Circulation. 1997;95:240–244.[Abstract/Free Full Text]

80. Verhagen AMG, Rabelink TJ, Braam B, Opgenorth TJ, Grone HJ, Koomans HA, Joles JA. Endothelin A receptor blockade alleviates hypertension and renal lesions associated with chronic nitric oxide synthase inhibition. J Am Soc Nephrol. 1998;9:755–762.[Abstract]

81. Quignard JF, Frapier JM, Harricane MC, Albat B, Nargeot J, Richard S. Voltage-gated calcium channel currents in human coronary myocytes. Regulation by cyclic GMP and nitric oxide. J Clin Invest. 1997;99:185–193.[Medline] [Order article via Infotrieve]

82. Meszaros LG, Minarovic I, Zahradnikova A. Inhibition of the skeletal muscle ryanodine receptor calcium release channel by nitric oxide. FEBS Lett. 1996;380:49–52.[Medline] [Order article via Infotrieve]

83. Ribeiro MO, Antunes E, Muscara MN, De Nucci G, Zatz R. Nifedipine prevents renal injury in rats with chronic nitric oxide inhibition. Hypertension. 1995;26:150–155.[Abstract/Free Full Text]

84. Mattson DL, Lu S, Nakanishi K, Papanek PE, Cowley AW Jr. Effect of chronic renal medullary nitric oxide inhibition on blood pressure. Am J Physiol. 1994;266:H1918–H1926.[Abstract/Free Full Text]

85. Chen PY, Sanders PW. L-Arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest. 1991;88:1559–1567.

86. Tolins JP, Shultz PJ. Endogenous nitric oxide synthesis determines sensitivity to the presser effect of salt. Kidney Int. 1994;46:230–236.[Medline] [Order article via Infotrieve]

87. Salazar FJ, Alberola A, Pinilla JM, Romero JC, Quesada T. Salt-induced increase in arterial pressure during nitric oxide synthesis inhibition. Hypertension. 1993;22:49–55.[Abstract/Free Full Text]

88. Fernandez-Rivas A, Garcia-Estan J, Vargas F. Effects of chronic increased salt intake on nitric oxide synthesis inhibition-induced hypertension. J Hypertens. 1995;13:123–128.[Medline] [Order article via Infotrieve]

89. Salvemini D, Masferrer JL. Interactions of nitric oxide with cyclooxygenase: in vitro, ex vivo and in vivo studies. Methods Enzymol. 1996;269:12–25.[Medline] [Order article via Infotrieve]

90. Marotta P, Sautebin L, Di Rosa M. Modulation of the induction of nitric oxide synthase by eicosanoids in the murine macrophage cell line J774. Br J Pharmacol. 1992;107:640–641.[Medline] [Order article via Infotrieve]

91. Luckhoff A, Mulsch A, Busse R. cAMP attenuates autocoid release from endothelial cells: relation to internal calcium. Am J Physiol. 1990;258:H960–H966.[Abstract/Free Full Text]

92. Lahera V, Salom MG, Fiksen-Olsen MJ, Raij L, Romero JC. Effects of N^G-monomethyl-L-arginine and L-arginine on acetylcholine renal response. Hypertension. 1990;15:659–663.[Abstract/Free Full Text]

93. Baylis C, Slangen B, Hussain S, Weaver C. Relationship between basal NO release and cyclooxygenase products in the normal rat kidney. Am J Physiol. 1996;271:R1327–R1334.[Abstract/Free Full Text]

94. Harder DR, Lange AR, Gebremedhin D, Birks EK, Roman RJ. Cytochrome P450 metabolites of arachidonic acid as intracellular signaling molecules in vascular tissue. J Vasc Res. 1997;34:237–243.[Medline] [Order article via Infotrieve]

95. Nakatsuka M, Osawa Y. Selective inhibition of the 12-lipoxygenase pathway of arachidonic acid metabolism by L-arginine or sodium nitroprusside in intact human platelets. Biochem Biophys Res Commun. 1994;200:1630–1634.[Medline] [Order article via Infotrieve]

96. Nicotera P, Brune B, Bagetta G. Nitric oxide: inducer or suppressor of apoptosis? Trends Pharmacol Sci. 1997;18:189–190.[Medline] [Order article via Infotrieve]

97. Dubey RK, Jackson EK, Rupprecht HD, Sterzel RB. Factors controlling growth and matrix production in vascular smooth muscle and glomerular mesangial cells. Curr Opin Nephrol Hypertens. 1997;6:88–105.[Medline] [Order article via Infotrieve]

98. Moreno H, Metze K, Bento AC, Antunes E, Zatz R, De Nucci G. Chronic nitric oxide inhibition as a model of hypertensive heart muscle disease. Basic Res Cardiol. 1996;91:248–255.[Medline] [Order article via Infotrieve]

99. Banting JD, Thompson KE, Friberg P, Adams MA. Blunted cardiovascular growth induction during prolonged nitric oxide synthase blockade. Hypertension. 1997;30:416–421.[Abstract/Free Full Text]

100. Heptinstall RH. Hypertension. In: Heptinstall RH, ed. Pathology of the Kidney. Boston, Mass: Little Brown & Co; 1983:1347–1454.

101. Meyer TW, Rennke HG. Progressive glomerular injury after limited renal infarction in the rat. Am J Physiol. 1988;254:F856–F862.[Abstract/Free Full Text]

102. Arcos MI, Fujihara C, Sesso A, Prado EBA, Prado MJA, Vasques W, Correia H, De Nucci G, Zatz R. Mechanisms of proteinuria in the chronic nitric oxide inhibition model. J Am Soc Nephrol. 1996;7:1558. Abstract.

103. Numaguchi K, Egashira K, Takemoto M, Kadokami T, Shimokawa H, Sueishi K, Takeshita A. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension. 1995;26:957–962.[Abstract/Free Full Text]

104. Moreno H, Nathan LP, Costa SKP, Metze K, Antunes E, Zatz R, De Nucci G. Enalapril does not prevent the myocardial ischemia caused by the chronic inhibition of nitric oxide synthesis. Eur. J Pharmacol. 1995;287:93–96.[Medline] [Order article via Infotrieve]

105. Ikeda K, Gu D, Nara Y, Tagami M, Yamori Y. New stroke model from normotensive Wistar-Kyoto rats by chronic nitric oxide synthesis inhibition. J Hypertens. 1994;12(suppl 3):S3. Abstract.

106. Blot S, Arnal JF, Xu Y, Gray F, Michel JB. Spinal cord infarcts during long-term inhibition of nitric oxide synthase in rats. Stroke. 1994;25:1666–1673.[Abstract]

This article has been cited by other articles:

				T. J. M. Roberts, A. C. Chapman, and M. J. Cipolla PPAR-{gamma} agonist rosiglitazone reverses increased cerebral venous hydraulic conductivity during hypertension Am J Physiol Heart Circ Physiol, October 1, 2009; 297(4): H1347 - H1353. [Abstract] [Full Text] [PDF]

				O. Kuru, U. K. Senturk, G. Kocer, S. Ozdem, O. K. Baskurt, A. Cetin, A. Yesilkaya, and F. Gunduz Effect of exercise training on resistance arteries in rats with chronic NOS inhibition J Appl Physiol, September 1, 2009; 107(3): 896 - 902. [Abstract] [Full Text] [PDF]

				M. Carlstrom, R. D. Brown, J. Edlund, J. Sallstrom, E. Larsson, T. Teerlink, F. Palm, N. Wahlin, and A. E. G. Persson Role of nitric oxide deficiency in the development of hypertension in hydronephrotic animals Am J Physiol Renal Physiol, February 1, 2008; 294(2): F362 - F370. [Abstract] [Full Text] [PDF]

				C. Baylis Nitric oxide deficiency in chronic kidney disease Am J Physiol Renal Physiol, January 1, 2008; 294(1): F1 - F9. [Abstract] [Full Text] [PDF]

				M. P. Koeners, E. E. van Faassen, S. Wesseling, M. de Sain-van der Velden, H. A. Koomans, B. Braam, and J. A. Joles Maternal Supplementation With Citrulline Increases Renal Nitric Oxide in Young Spontaneously Hypertensive Rats and Has Long-Term Antihypertensive Effects Hypertension, December 1, 2007; 50(6): 1077 - 1084. [Abstract] [Full Text] [PDF]

				S. B. Ahmed, N. D.L. Fisher, and N. K. Hollenberg Gender and the Renal Nitric Oxide Synthase System in Healthy Humans Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 926 - 931. [Abstract] [Full Text] [PDF]

				T. Yamashita, E. Yamamoto, K. Kataoka, T. Nakamura, S. Matsuba, Y. Tokutomi, Y.-F. Dong, H. Ichijo, H. Ogawa, and S. Kim-Mitsuyama Apoptosis Signal-Regulating Kinase-1 Is Involved in Vascular Endothelial and Cardiac Remodeling Caused by Nitric Oxide Deficiency Hypertension, September 1, 2007; 50(3): 519 - 524. [Abstract] [Full Text] [PDF]

				S. E. O'Sullivan, M. D. Randall, and S. M. Gardiner The in Vitro and in Vivo Cardiovascular Effects of {Delta}9-Tetrahydrocannabinol in Rats Made Hypertensive by Chronic Inhibition of Nitric-Oxide Synthase J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 663 - 672. [Abstract] [Full Text] [PDF]

				S. Wesseling, J. A. Joles, H. van Goor, H. A. Bluyssen, P. Kemmeren, F. C. Holstege, H. A. Koomans, and B. Braam Transcriptome-based identification of pro- and antioxidative gene expression in kidney cortex of nitric oxide-depleted rats Physiol Genomics, January 17, 2007; 28(2): 158 - 167. [Abstract] [Full Text] [PDF]

				F. Vargas, J. M. Moreno, R. Wangensteen, I. Rodriguez-Gomez, and J. Garcia-Estan The endocrine system in chronic nitric oxide deficiency Eur. J. Endocrinol., January 1, 2007; 156(1): 1 - 12. [Abstract] [Full Text] [PDF]

				A. Erdely, G. Freshour, Y.-L. Tain, K. Engels, and C. Baylis DOCA/NaCl-induced chronic kidney disease: a comparison of renal nitric oxide production in resistant and susceptible rat strains Am J Physiol Renal Physiol, January 1, 2007; 292(1): F192 - F196. [Abstract] [Full Text] [PDF]

				E. O'Riordan, N. Mendelev, S. Patschan, D. Patschan, J. Eskander, L. Cohen-Gould, P. Chander, and M. S. Goligorsky Chronic NOS inhibition actuates endothelial-mesenchymal transformation Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H285 - H294. [Abstract] [Full Text] [PDF]

				H. L. Hillege and D. J. van Veldhuisen Response to Letter Regarding Article, "Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure" Circulation, August 8, 2006; 114(6): e243 - e243. [Full Text] [PDF]

				F. Vargas, J. M. Moreno, I. Rodriguez-Gomez, R. Wangensteen, A. Osuna, M. Alvarez-Guerra, and J. Garcia-Estan Vascular and renal function in experimental thyroid disorders Eur. J. Endocrinol., February 1, 2006; 154(2): 197 - 212. [Abstract] [Full Text] [PDF]

				S. Wesseling, D. A. Ishola Jr., J. A. Joles, H. A. Bluyssen, H. A. Koomans, and B. Braam Resistance to oxidative stress by chronic infusion of angiotensin II in mouse kidney is not mediated by the AT2 receptor Am J Physiol Renal Physiol, June 1, 2005; 288(6): F1191 - F1200. [Abstract] [Full Text] [PDF]

				M. Michalkiewicz, G. Zhao, Z. Jia, T. Michalkiewicz, and M. J. Racadio Central Neuropeptide Y Signaling Ameliorates N({omega})-Nitro-L-Arginine Methyl Ester Hypertension in the Rat Through a Y1 Receptor Mechanism Hypertension, April 1, 2005; 45(4): 780 - 785. [Abstract] [Full Text] [PDF]

				J. Shearer, P. T. Fueger, J. N. Rottman, D. P. Bracy, P. H. Martin, and D. H. Wasserman AMPK stimulation increases LCFA but not glucose clearance in cardiac muscle in vivo Am J Physiol Endocrinol Metab, November 1, 2004; 287(5): E871 - E877. [Abstract] [Full Text] [PDF]

				R. Rossi, E. Chiurlia, A. Nuzzo, E. Cioni, G. Origliani, and M. G. Modena Flow-mediated vasodilation and the risk of developing hypertension in healthy postmenopausal women J. Am. Coll. Cardiol., October 19, 2004; 44(8): 1636 - 1640. [Abstract] [Full Text] [PDF]

				A. Erdely, G. Freshour, C. Smith, K. Engels, J. L. Olson, and C. Baylis Protection against puromycin aminonucleoside-induced chronic renal disease in the Wistar-Furth rat Am J Physiol Renal Physiol, July 1, 2004; 287(1): F81 - F89. [Abstract] [Full Text] [PDF]

				J. Shearer, P. T. Fueger, B. Vorndick, D. P. Bracy, J. N. Rottman, J. A. Clanton, and D. H. Wasserman AMP Kinase-Induced Skeletal Muscle Glucose But Not Long-Chain Fatty Acid Uptake Is Dependent on Nitric Oxide Diabetes, June 1, 2004; 53(6): 1429 - 1435. [Abstract] [Full Text] [PDF]

				D. M. Attia, O. Feron, R. Goldschmeding, L. H. Radermakers, N. D. Vaziri, P. Boer, J.-L. Balligand, H. A. Koomans, and J. A. Joles Hypercholesterolemia in Rats Induces Podocyte Stress and Decreases Renal Cortical Nitric Oxide Synthesis via an Angiotensin II Type 1 Receptor-Sensitive Mechanism J. Am. Soc. Nephrol., April 1, 2004; 15(4): 949 - 957. [Abstract] [Full Text] [PDF]

				J. Sainz, A. Osuna, R. Wangensteen, J. de Dios Luna, I. Rodriguez-Gomez, J. Duarte, J. M. Moreno, and F. Vargas Role of sex, gonadectomy and sex hormones in the development of nitric oxide inhibition-induced hypertension Exp Physiol, March 1, 2004; 89(2): 155 - 162. [Abstract] [Full Text] [PDF]

				K. Ito, Y. Hirooka, T. Kishi, Y. Kimura, K. Kaibuchi, H. Shimokawa, and A. Takeshita Rho/Rho-Kinase Pathway in the Brainstem Contributes to Hypertension Caused by Chronic Nitric Oxide Synthase Inhibition Hypertension, February 1, 2004; 43(2): 156 - 162. [Abstract] [Full Text] [PDF]

				J. M. Canty Jr and J. A. Fallavollita Sympathetic Nerves and Myocyte Necrosis: More Than Meets the Eye Circ. Res., October 31, 2003; 93(9): 796 - 798. [Full Text] [PDF]

				A. Erdely, L. Wagner, V. Muller, A. Szabo, and C. Baylis Protection of Wistar Furth Rats from Chronic Renal Disease Is Associated with Maintained Renal Nitric Oxide Synthase J. Am. Soc. Nephrol., October 1, 2003; 14(10): 2526 - 2533. [Abstract] [Full Text] [PDF]

				I. Rodriguez-Gomez, J. Sainz, R. Wangensteen, J. M. Moreno, J. Duarte, A. Osuna, and F. Vargas Increased Pressor Sensitivity to Chronic Nitric Oxide Deficiency in Hyperthyroid Rats Hypertension, August 1, 2003; 42(2): 220 - 225. [Abstract] [Full Text] [PDF]

				J.-J. Boffa, Y. Lu, S. Placier, A. Stefanski, J.-C. Dussaule, and C. Chatziantoniou Regression of Renal Vascular and Glomerular Fibrosis: Role of Angiotensin II Receptor Antagonism and Matrix Metalloproteinases J. Am. Soc. Nephrol., May 1, 2003; 14(5): 1132 - 1144. [Abstract] [Full Text] [PDF]

				U. Wisloff, R. S Richardson, and A. O Brubakk NOS inhibition increases bubble formation and reduces survival in sedentary but not exercised rats J. Physiol., January 15, 2003; 546(2): 577 - 582. [Abstract] [Full Text] [PDF]

				M.-C. Bouton, B. Richard, P. Rossignol, M. Philippe, M.-C. Guillin, J.-B. Michel, and M. Jandrot-Perrus The Serpin Protease-Nexin 1 Is Present in Rat Aortic Smooth Muscle Cells and Is Upregulated in L-NAME Hypertensive Rats Arterioscler Thromb Vasc Biol, January 13, 2003; 23(1): 142 - 147. [Abstract] [Full Text] [PDF]

				S. Gschwend, H. Buikema, G. Navis, R. H. Henning, D. de Zeeuw, and R. P. E. van Dokkum Endothelial Dilatory Function Predicts Individual Susceptibility to Renal Damage in the 5/6 Nephrectomized Rat J. Am. Soc. Nephrol., December 1, 2002; 13(12): 2909 - 2915. [Abstract] [Full Text] [PDF]

				S. Bapat, J. A. Post, B. Braam, R. Goldschmeding, H. A. Koomans, A. J. Verkleij, and J. A. Joles Visualizing Tubular Lipid Peroxidation in Intact Renal Tissue in Hypertensive Rats J. Am. Soc. Nephrol., December 1, 2002; 13(12): 2990 - 2996. [Abstract] [Full Text] [PDF]

				C. K. Fujihara, A. L. Mattar, J. M. Vieira Jr, D. M. A. C. Malheiros, I. d. L. Noronha, A. R. R. Goncalves, G. de Nucci, and R. Zatz Evidence for the Existence of Two Distinct Functions for the Inducible NO Synthase in the Rat Kidney: Effect of Aminoguanidine in Rats with 5/6 Ablation J. Am. Soc. Nephrol., September 1, 2002; 13(9): 2278 - 2287. [Abstract] [Full Text] [PDF]

				D.-H. Kang, T. Nakagawa, L. Feng, and R. J. Johnson Nitric Oxide Modulates Vascular Disease in the Remnant Kidney Model Am. J. Pathol., July 1, 2002; 161(1): 239 - 248. [Abstract] [Full Text] [PDF]

				J. N. Rottman, D. Bracy, C. Malabanan, Z. Yue, J. Clanton, and D. H. Wasserman Contrasting effects of exercise and NOS inhibition on tissue-specific fatty acid and glucose uptake in mice Am J Physiol Endocrinol Metab, July 1, 2002; 283(1): E116 - E123. [Abstract] [Full Text] [PDF]

				D. M. Attia, A. M. G. Verhagen, E. S. G. Stroes, E. E. van Faassen, H.-J. Grone, S. J. De Kimpe, H. A. Koomans, B. Braam, and J. A. Joles Vitamin E Alleviates Renal Injury, but Not Hypertension, during Chronic Nitric Oxide Synthase Inhibition in Rats J. Am. Soc. Nephrol., December 1, 2001; 12(12): 2585 - 2593. [Abstract] [Full Text] [PDF]

				H. Mukundan and N. L. Kanagy Ca2+ influx mediates enhanced alpha 2-adrenergic contraction in aortas from rats treated with NOS inhibitor Am J Physiol Heart Circ Physiol, November 1, 2001; 281(5): H2233 - H2240. [Abstract] [Full Text] [PDF]

				S.-I. Suga, M. I. Phillips, P. E. Ray, J. A. Raleigh, C. P. Vio, Y.-G. Kim, M. Mazzali, K. L. Gordon, J. Hughes, and R. J. Johnson Hypokalemia induces renal injury and alterations in vasoactive mediators that favor salt sensitivity Am J Physiol Renal Physiol, October 1, 2001; 281(4): F620 - F629. [Abstract] [Full Text] [PDF]

				K. Kaikita, A. B. Fogo, L. Ma, J. A. Schoenhard, N. J. Brown, and D. E. Vaughan Plasminogen Activator Inhibitor-1 Deficiency Prevents Hypertension and Vascular Fibrosis in Response to Long-term Nitric Oxide Synthase Inhibition Circulation, August 14, 2001; 104(7): 839 - 844. [Abstract] [Full Text] [PDF]

				P. PERINOTTO, A. BIGGI, N. CARRA, A. ORRICO, G. VALMADRE, P. DALL'AGLIO, A. NOVARINI, and A. MONTANARI Angiotensin II and Prostaglandin Interactions on Systemic and Renal Effects of L-NAME in Humans J. Am. Soc. Nephrol., August 1, 2001; 12(8): 1706 - 1712. [Abstract] [Full Text] [PDF]

				Y. Quiroz, H. Pons, K. L. Gordon, J. Rincon, M. Chavez, G. Parra, J. Herrera-Acosta, D. Gomez-Garre, R. Largo, J. Egido, et al. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition Am J Physiol Renal Physiol, July 1, 2001; 281(1): F38 - F47. [Abstract] [Full Text] [PDF]

				D. Casellas, A. Herizi, A. Artuso, A. Mimran, and B. Jover Candesartan prevents L-NAME-induced cardio-renal injury in spontaneously hypertensive rats beyond hypotensive effects Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S84 - S90. [Abstract] [PDF]

				M. C. DE GRACIA, A. OSUNA, F. O'VALLE, R. G. DEL MORAL, R. WANGENSTEEN, C. G. DEL RIO, and F. VARGAS Deoxycorticosterone Suppresses the Effects of Losartan in Nitric Oxide--Deficient Hypertensive Rats J. Am. Soc. Nephrol., November 1, 2000; 11(11): 1995 - 2000. [Abstract] [Full Text]

				T. Rankinen, T. Rice, L. Perusse, Y. C. Chagnon, J. Gagnon, A. S. Leon, J. S. Skinner, J. H. Wilmore, D. C. Rao, and C. Bouchard NOS3 Glu298Asp Genotype and Blood Pressure Response to Endurance Training : The HERITAGE Family Study Hypertension, November 1, 2000; 36(5): 885 - 889. [Abstract] [Full Text] [PDF]

				S. M. Fitzgerald and M. W. Brands Nitric oxide may be required to prevent hypertension at the onset of diabetes Am J Physiol Endocrinol Metab, October 1, 2000; 279(4): E762 - E768. [Abstract] [Full Text] [PDF]

				K. Eshima, Y. Hirooka, H. Shigematsu, I. Matsuo, G. Koike, K. Sakai, and A. Takeshita Angiotensin in the Nucleus Tractus Solitarii Contributes to Neurogenic Hypertension Caused by Chronic Nitric Oxide Synthase Inhibition Hypertension, August 1, 2000; 36(2): 259 - 263. [Abstract] [Full Text] [PDF]

				G. Alvarez, A. Osuna, R. Wangensteen, and F. Vargas Interaction Between Nitric Oxide and Mineralocorticoids in the Long-Term Control of Blood Pressure Hypertension, March 1, 2000; 35(3): 752 - 757. [Abstract] [Full Text] [PDF]

				C. Loichot, C. Cazaubon, M. Grima, W. De Jong, D. Nisato, J.-L. Imbs, and M. Barthelmebs Vasopressin Does not Effect Hypertension Caused by Long-Term Nitric Oxide Inhibition Hypertension, February 1, 2000; 35(2): 602 - 608. [Abstract] [Full Text] [PDF]

				S. M. Gardiner, W. R. Dunn, T. Bennett, R. Zatz, and C. Baylis Chronic Nitric Oxide Inhibition Model Six Years On • Response Hypertension, November 1, 1999; e4(5): . [Full Text]

				C. T. Bergamaschi, R. R. Campos, and O. U. Lopes Rostral Ventrolateral Medulla : A Source of Sympathetic Activation in Rats Subjected to Long-Term Treatment With L-NAME Hypertension, October 1, 1999; 34(4): 744 - 747. [Abstract] [Full Text] [PDF]

				S. P. Salas, J. F. Vuletin, A. Giacaman, P. Rosso, and C. P. Vio Long-Term Nitric Oxide Synthase Inhibition in Rat Pregnancy Reduces Renal Kallikrein Hypertension, October 1, 1999; 34(4): 865 - 871. [Abstract] [Full Text] [PDF]

				S. M. Fitzgerald and M. W. Brands Hypertension in L-NAME-treated diabetic rats depends on an intact sympathetic nervous system Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2002; 282(4): R1070 - R1076. [Abstract] [Full Text] [PDF]

				W. H. Beierwaltes, D'A. L. Potter, and E. G. Shesely Renal baroreceptor-stimulated renin in the eNOS knockout mouse Am J Physiol Renal Physiol, January 1, 2002; 282(1): F59 - F64. [Abstract] [Full Text] [PDF]

				X. Wang and R. Loutzenhiser Determinants of renal microvascular response to ACh: afferent and efferent arteriolar actions of EDHF Am J Physiol Renal Physiol, January 1, 2002; 282(1): F124 - F132. [Abstract] [Full Text] [PDF]

This Article Extract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zatz, R. Articles by Baylis, C. Search for Related Content PubMed PubMed Citation Articles by Zatz, R. Articles by Baylis, C.